Skip to main content
SpringerLink
Log in

My View on the Biological Features and Surgical Treatment of Liver Cancer

  • Chapter
  • First Online:
Surgical Pathology of Hepatobiliary Tumors

Abstract

Pathology is the prerequisite for oncology surgeons to make decisions. I can only feel grateful for the contribution made by my fellow pathologists. Having the honor to write a passage for the introduction to this monograph, I am even more overwhelmed. After all, I’m only a clinician, not a basic research fellow. Fortunately there are the two words “my view” in my title. Therefore this passage will just be my personal opinions from the clinical perspective for the reference of those engaged in the same pursuit.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207–14.

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  3. Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475–83.

    Article  PubMed  Google Scholar 

  4. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinoma using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416–23.

    Article  CAS  PubMed  Google Scholar 

  5. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012–24.

    Article  CAS  PubMed  Google Scholar 

  6. Jia QA, Ren ZG, Bu Y, et al. Herbal compound “Songyou Yin” renders hepatocellular carcinoma sensitive to oxaliplatin through inhibition of stemness. Evid Based Complem Altern Med. 2012;2012:908601.

    Google Scholar 

  7. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:1–13.

    Article  Google Scholar 

  8. Malanchi I, Santamaria-Martínez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481:85–9.

    Article  PubMed  Google Scholar 

  9. Jia QA, Wang ZM, Ren ZG, et al. Herbal compound “Songyou Yin” attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complem Altern Med. 2013;13:89.

    Article  Google Scholar 

  10. Yamauchi K, Yang M, Hayashi K, et al. Induction of metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008;15(68):516–20.

    Article  Google Scholar 

  11. Altekruse SF, McGlynn KA, Dickie LA, et al. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology. 2012;55:476–82.

    Article  PubMed  Google Scholar 

  12. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405.

    Article  PubMed  Google Scholar 

  13. Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.

    Article  PubMed  Google Scholar 

  14. Pang JZ, Qin LX, Ren N, et al. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with Tumor-Node-Metastasis Stage I of hepatocellular carcinoma. Clin Cancer Res. 2007;13:7363–9.

    Article  CAS  Google Scholar 

  15. Huang XY, Huang ZL, Wang L, et al. Herbal compound “Songyou Yin” reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice. BMC Cancer. 2010;10:580–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Tang ZY, Yu YQ, Zhou XD, et al. Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol. 1991;47:27–31.

    Article  CAS  PubMed  Google Scholar 

  17. Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013;58:81–8.

    Article  CAS  PubMed  Google Scholar 

  18. Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology. 2011;53:483–92.

    Article  CAS  PubMed  Google Scholar 

  19. Wang L, Tang ZY, Qin LX, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 2000;32:43–8.

    Article  CAS  PubMed  Google Scholar 

  20. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–65.

    Article  CAS  PubMed  Google Scholar 

  21. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140:935–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al. Nonsteriodal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:1808–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hsu, et al. Postoperative peg-interferon plus ribavirin associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58:150–7.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARa oncoprotein by directly binding PML. Science. 2010;328:240–3.

    Article  CAS  PubMed  Google Scholar 

  26. Wang WQ, Liu L, Sun HC, et al. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J Hematol Oncol. 2012;5:69–79.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Liu L, Ren ZG, Shen Y, et al. Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: relevance of epithelial-mesenchymal transition. Cancer Sci. 2010;101:120–8.

    Article  CAS  PubMed  Google Scholar 

  28. Liu L, Zhu XD, Wang WQ, et al. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res. 2010;16:2740–50.

    Article  CAS  PubMed  Google Scholar 

  29. Sun FX, Tang ZY, Liu KD, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996;66:239–43.

    Article  CAS  PubMed  Google Scholar 

  30. Tian J, Tang ZY, Ye SL, et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expression of the factors associated with metastasis. Br J Cancer. 1999;81:814–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Li T, Zeng ZC, Wang L, et al. Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial–mesenchymal transition. Cancer Gene Ther. 2011;18:617–26.

    Article  CAS  PubMed  Google Scholar 

  32. Xiong W, Ren ZG, Qiu SJ, et al. Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer. 2010;10:219–30.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Zhang W, Sun HC, Wang WQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology. 2012;143:1641–9.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang QB, Sun HC, Zhang KZ, et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One. 2013;8:e55945.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zhu XD, Sun HC, Xu HX, et al. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis. 2013;16:809–20.

    Article  CAS  PubMed  Google Scholar 

  36. Huang Q, Li F, Liu X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17:860–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Casanovas O. Cancer: limitation of therapies exposed. Nature. 2012;484:44–6.

    Article  CAS  PubMed  Google Scholar 

  38. Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010;16:3420–30.

    Article  CAS  PubMed  Google Scholar 

  39. Huang XY, Wang L, Huang ZL, et al. Herbal extract “Songyou Yin” inhibits tumor growth and prolongs survival in nude mice bearing human hepatocellular carcinoma xenograft with high metastatic potential. J Cancer Res Clin Oncol. 2009;135:1245–55.

    Article  PubMed  Google Scholar 

  40. Jia JB, Wang WQ, Sun HC, et al. A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice. Investig New Drugs. 2010;29:861–72.

    Article  Google Scholar 

  41. Entschladen F, Drell 4th TL, Lang K, et al. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004;5:254–8.

    Article  CAS  PubMed  Google Scholar 

  42. Ondicova K, Mravec B. Role of nervous system in cancer aetiopathogenesis. Lancet Oncol. 2010;11:596–601.

    Article  PubMed  Google Scholar 

  43. Schreiber RD, Old LJ, Smyth MJ, et al. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.

    Article  CAS  PubMed  Google Scholar 

  44. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148:1081–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465:803–7.

    Article  CAS  PubMed  Google Scholar 

  46. Israelsen WJ, Vander Heiden MG. ATP consumption promotes cancer metabolism. Cell. 2010;143:669–71.

    Article  CAS  PubMed  Google Scholar 

  47. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Garcia-Cao I, Song MS, Hobbs RM, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012;149:49–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Krall AS, Christofk HR. Cancer: a metabolic metamorphosis. Nature. 2013;496:38–40.

    Article  CAS  PubMed  Google Scholar 

  50. Ji JF, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academician of Chinese Academy of Sciences, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

    Zhao-You Tang

Authors
  1. Zhao-You Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhao-You Tang .

Editor information

Editors and Affiliations

  1. Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

    Wen-Ming Cong

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd. and People's Medical Publishing House

About this chapter

Cite this chapter

Tang, ZY. (2017). My View on the Biological Features and Surgical Treatment of Liver Cancer. In: Cong, WM. (eds) Surgical Pathology of Hepatobiliary Tumors. Springer, Singapore. https://doi.org/10.1007/978-981-10-3536-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-3536-4_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-3535-7

  • Online ISBN: 978-981-10-3536-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation